Zein N N, Germer J J, Wendt N K, Schimek C M, Thorvilson J N, Mitchell P S, Persing D H
Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
J Clin Microbiol. 1997 Jan;35(1):311-2. doi: 10.1128/jcm.35.1.311-312.1997.
A second-generation recombinant immunoblot assay (RIBA 2.0) is used in the United States to confirm infection with hepatitis C virus (HCV) in samples that are anti-HCV (enzyme immunoassay) positive. In some cases, indeterminate results of RIBA 2.0, which are defined as reactivity to a single antigen species or reactivity limited to two proteins derived from the same coding region of the HCV genome, are encountered. This study was performed to establish the significance of indeterminate RIBA 2.0 results in relation to HCV RNA detection, high positivity for the c22-3 band, and the HCV genotype as determined by direct DNA sequencing. Ninety-six samples with indeterminate RIBA 2.0 results were studied. HCV RNA was detected in 21 of 34 (62%) samples with high reactivity to c22-3 and in 8 of 62 (13%) samples with low reactivity to c22-3. The HCV genotype distribution in samples that were RIBA 2.0 indeterminate and HCV RNA positive was significantly different from that in samples of a control group with positive results for both the RIBA 2.0 and HCV PCR. These results suggest that highly positive c22-3 samples are likely to be associated with HCV viremia and that infection with less common HCV genotypes is more commonly associated with indeterminate RIBA 2.0 results.
在美国，第二代重组免疫印迹法（RIBA 2.0）用于确认抗丙型肝炎病毒（HCV）（酶免疫测定）呈阳性的样本中是否感染了丙型肝炎病毒。在某些情况下，会遇到RIBA 2.0的不确定结果，其定义为对单一抗原种类有反应或反应仅限于源自HCV基因组同一编码区域的两种蛋白质。进行这项研究是为了确定RIBA 2.0不确定结果在HCV RNA检测、c22 - 3条带高阳性以及通过直接DNA测序确定的HCV基因型方面的意义。研究了96份RIBA 2.0结果不确定的样本。在对c22 - 3反应性高的34份样本中的21份（62%）以及对c22 - 3反应性低的62份样本中的8份（13%）检测到了HCV RNA。RIBA 2.0结果不确定且HCV RNA阳性的样本中的HCV基因型分布与RIBA 2.0和HCV PCR均呈阳性的对照组样本中的基因型分布显著不同。这些结果表明，c22 - 3高度阳性的样本可能与HCV病毒血症相关，并且感染较不常见的HCV基因型更常与RIBA 2.0不确定结果相关。
